Abstract
Introduction: Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-β (Aβ) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease- modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.
Keywords: Alzheimer’s disease, neurodegeneration, drug repositioning, tau protein, amyloid-β peptide, pharmacophores.
Current Alzheimer Research
Title:Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Volume: 15 Issue: 12
Author(s): Alexandre A. de Castro, Elaine F.F. da Cunha, Ander F. Pereira, Flavia V. Soares, Daniel H.S. Leal, Kamil Kuca and Teodorico C. Ramalho*
Affiliation:
- Department of Chemistry, Federal University of Lavras, Lavras/MG, 37200-000,Brazil
Keywords: Alzheimer’s disease, neurodegeneration, drug repositioning, tau protein, amyloid-β peptide, pharmacophores.
Abstract: Introduction: Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-β (Aβ) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease- modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.
Export Options
About this article
Cite this article as:
de Castro A. Alexandre, da Cunha F.F. Elaine , Pereira F. Ander , Soares V. Flavia, Leal H.S. Daniel , Kuca Kamil and Ramalho C. Teodorico *, Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives, Current Alzheimer Research 2018; 15 (12) . https://dx.doi.org/10.2174/1567205015666180813150703
DOI https://dx.doi.org/10.2174/1567205015666180813150703 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acetylcholinesterase Inhibitor Donepezil Effects on Plasma β-Hydroxybutyrate Levels in the Treatment of Alzheimer’s Disease
Current Alzheimer Research Natural and Synthetic Inhibitors of Caspases: Targets for Novel Drugs
Current Drug Targets - CNS & Neurological Disorders EDITORIAL: “The Faces of Mania: The Legacy of Athanasios Koukopoulos”
Current Neuropharmacology Investigation of the CYP2C9 Induction Profile in Human Hepatocytes by Combining Experimental and Modelling Approaches
Current Drug Metabolism Diagnosis and Possible Use of Traditional Medicinal Plant to combat COVID-19
Coronaviruses Cytoprotection by Melatonin, Precursors and Metabolites in an In Vitro Model of Neurotoxicity Induced by Okadaic Acid
Letters in Drug Design & Discovery Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Quality Indicators for Depression Treatment in Primary Care: A Systematic Literature Review
Current Psychiatry Reviews Viral Gastroenteritis in Adults
Recent Patents on Anti-Infective Drug Discovery Detection of Unilateral Hearing Loss by Stationary Wavelet Entropy
CNS & Neurological Disorders - Drug Targets Evidence that Enzyme Processivity Mediates Differential Aβ Production by PS1 and PS2
Current Alzheimer Research The Progress of Epilepsy after Stroke
Current Neuropharmacology The Immunologic Barriers to Replacing Damaged Organs
Current Immunology Reviews (Discontinued) Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Radial Glia-endothelial Cells’ Bidirectional Interactions Control Vascular Maturation and Astrocyte Differentiation: Impact for Blood-brain Barrier Formation
Current Neurovascular Research Adolescence and Borderline Behavior - Between Personality Development and Personality Disorder
Adolescent Psychiatry Mental and Emotional Wellbeing During the COVID-19 Pandemic: The Unprecedented Malaysian Experience
Current Psychiatry Research and Reviews Antidotes for Acute Cyanide Poisoning
Current Pharmaceutical Biotechnology Autophagy in Diabetic Retinopathy
Current Neuropharmacology Anti-Androgen Drugs in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Current Medicinal Chemistry